Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence Study of HRS9531 Injection in Multi-dose vs Single-dose Pens
NCT06792955Phase 1Completed
- Sponsor
- Fujian Shengdi Pharmaceuticals
- Start
- Feb 2025
- Primary completion
- Jun 2025
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of HRS9531 in Overweight and obesity (2 arms), sponsored by Fujian Shengdi Pharmaceuticals. Primary endpoints: Maximum Plasma Concentration, Area Under the Concentration Curve from Time 0 to Last Quantifiable Concentration and 1 more. Started Feb 2025; status: completed.
02
Drugs
HRS9531
03
Conditions
Overweightobesity
Beyond the preview
Go deeper on NCT06792955.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06792955.